HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon Q4 and 2006

This article was originally published in The Rose Sheet

Executive Summary

Lower shipments of color cosmetics resulted in a 20.7% plunge in U.S. sales to $227.1 mil. for the fiscal year 2006 fourth quarter (ended Dec. 31), Revlon announces March 13. International sales remained flat at $151.8 mil., as low-single-digit declines in Asia Pacific and Europe offset double-digit growth in Latin America, firm says. Overall, Q4 sales dropped 13.5% from the prior-year period to $378.9 mil., as the firm continues its "organizational streamlining" following the September discontinuance of Vital Radiance. For the full year, sales were flat at $1.33 bil. Domestic sales declined 3% to $764.9 mil., with higher sales of Revlon and Almay partially compensating for the Vital Radiance discontinuance. Internationally, sales grew 4.1% to $566.5 mil. on higher shipments in Europe and Latin America. Net loss in 2006 was $251.3 mil., compared with a net loss of $83.7 mil. in 2005. "Our results for the year reflect the important and costly decisions we have made to position Revlon for future success," Revlon President and CEO David Kennedy said, adding that the firm plans to focus on improving profitability and cash flow in 2007...

You may also be interested in...



Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel